Navigation Links
Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
Date:9/25/2007

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that enrollment is complete in its Chemophase(R) Phase I/IIa clinical trial for the treatment of superficial bladder cancer. The Company began dosing patients in this trial in April of last year, following the successful completion of the initial Phase I trial of a single-administration of Chemophase and mitomycin. Patient enrollment in this Phase I/IIa trial required stepwise enrollment by escalating dose cohort, with a pause for safety evaluation required after the last patient in the previous cohort had completed at least the first four of the six weekly study drug instillations. Chemophase is a novel recombinant investigational therapeutic being developed to enhance the delivery of chemotherapy.

The Chemophase Phase I/IIa clinical trial is a multi-center, open label, nonrandomized study to evaluate multiple intravesical (into the bladder) administrations of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer. This dose-finding Phase I/IIa study enrolled 27 patients with superficial bladder cancer. The objectives of the study included determining the maximum tolerated dose (MTD) and dose-limiting toxicities, if any, of escalating doses of mitomycin and then Chemophase in combination with mitomycin administered as weekly intravesical instillations for six weeks, consistent with the usual standard of care; establishing the optimal dose of Chemophase with mitomycin to be recommended for future studies; and observing patients for any preliminary evidenc
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Physician E-sampling is becoming well established across ... key marketing sales tactic in recent years. However, some ... a supplement to traditional sampling. According ... E-sampling has been seeded across multiple therapeutic areas- including ... has been in place for five or more years ...
(Date:9/4/2015)...  Janssen Research & Development, LLC (Janssen) announced ... has accepted for Priority Review the Biologics License ... patients with multiple myeloma who are refractory to ... agent (IMiD), or who have received three or ... and an IMiD. This is referred to as ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
(Date:9/4/2015)... Dallas, TX (PRWEB) , ... September 04, 2015 , ... ... in Iraq in 2007, will compete in the Ironman World Championships in Kona on ... veterans who have incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven Winter Associates, Inc., (SWA) ... been selected for the Residential Award of Merit by the Connecticut Green Building ... from a highly competitive field of submissions, the net-zero energy residence will be ...
(Date:9/4/2015)... Florida (PRWEB) , ... September 04, 2015 , ... ... ambulance and medical assistance company today announced that it has entered into a ... week, EMED signed an agreement to bridge the link between American healthcare, Jamaican ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to announce a ... norm not the exception. , St. Jude was recently named one of the nation’s ... making it one of only 10 hospitals in the state to earn the distinction. ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3
... found those with more of the male hormone in the ... -- New research out of Britain finds that financial traders ... testosterone tend to make more money that day, probably because ... traders with higher levels of the stress hormone cortisol tend ...
... ELMWOOD PARK, N.J. and NEW YORK, April 14 ,HLTH Corporation ... Health Corp. (Nasdaq: WBMD ), today announced that they ... March 31,2008 at approximately 4:00 pm (ET) on Tuesday, May ... pm (ET) on that day to discuss those,results., Investors ...
... macular degeneration, study finds , , MONDAY, April 14 (HealthDay ... lower risk of developing advanced age-related macular degeneration, especially ... a U.S. study finds. , Age-related macular degeneration (AMD) ... of vision loss and blindness among older adults, according ...
... sufferers, the Medicare Prescription Drug Improvement and Modernization ... management with biologic drugs. Prior to its passage ... tumor necrosis factor (TNF) inhibitors, the infusion ... Remicade. Since the MMA, most Medicare prescription drug ...
... Managed Market Teams Choose Best Plans for ... 14 Qforma, an advanced analytics,company, today ... Care,Optimization model. This innovative new tool was ... informed contracting and,pull-through strategies. iQMCO(TM) utilizes advanced ...
... exercise outside organized teams has drops as adolescence approaches, ... A record number of American girls are participating in ... sports are decreasing, especially as they go from childhood ... from the University of Minnesota Tucker Center for Research ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Hormone Replacement May Cut Risk for Age-Linked Eye Disease 2Health News:Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients 2Health News:Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients 3Health News:Qforma Unveils Managed Care Optimization Solution for Pharma Marketing Executives 2Health News:Girls Participating in Sports in Record Numbers 2
Shandon Slide Mailers and Envelopes...
Shandon Slide File Storage System...
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
... The Integre Duo is the ... proven,red and green wavelengths. This ... to instantly,select either a red ... which maximizes,treatment options and ensures ...
Medicine Products: